Pramod Srivastava, Ph.D., M.D. – Member, Board of Directors

Dr. Pramod K. Srivastava, an accomplished leader in basic and translational research, is the director of the Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center.

Dr. Srivastava is a professor and interim chair of the Department of Immunology, director of the Center for Immunotherapy of Cancer and Infectious Diseases, and part of the leadership team of the Connecticut Institute for Clinical and Translational Science (CICATS). He holds the Physicians Health Services Chair in Cancer Immunology.

He has earned international acclaim for his groundbreaking work in the immunological function of heat shock proteins and in cancer immunology, is widely published in scholarly journals and serves on editorial boards for several major journals in immunology.

He serves on the Scientific Advisory Council of the Cancer Research Institute and was a member of the Experimental Immunology Study Section of the National Institutes of Health of the U.S. Government (1994-1999). He serves on the editorial boards of a number of scholarly journals including Tissue Antigens and Human Vaccines. He has previously served on the editorial boards of the Journal of Immunology, Cellular Immunology, and Cell Stress and Chaperones. In 1997, he was inducted into the Roll of Honor of the International Union Against Cancer and was listed in Who’s Who in Science and Engineering, and several other Who’s Who’s. He is among the 20 founding members of the Academy of Cancer Immunology. Dr. Srivastava is the scientific founder of Antigenics (NASDAQ AGEN). He is also a co-founder of Ikonisys (New Haven, CT) and a co-founder of Life Science Pharmaceuticals (with James Fiore and Lloyd J Old MD).

Dr. Srivastava obtained his bachelor’s degree in biology and chemistry and a master’s degree in botany (paleontology) from the University of Allahabad, India. He then studied yeast genetics at Osaka University, Japan. He completed his Ph.D. in biochemistry at the Center for Cellular and Molecular Biology, Hyderabad, India, where he began his work on tumor immunity, including identification of the first proteins that can mediate tumor rejection. He trained at Yale University and Sloan-Kettering Institute for Cancer Research. Dr. Srivastava has previously held faculty positions at the Mount Sinai School of Medicine and Fordham University in New York City.